Skip to Content

Join the 'Ovarian Cancer' group to help and get support from people like you.

Ovarian Cancer News

Related terms: Cancer, Ovarian, Cancer, Ovaries

Daily Low-Dose Aspirin May Be Weapon Against Ovarian Cancer

Posted 2 days ago by Drugs.com

FRIDAY, July 20, 2018 – One low-dose aspirin a day could help women avoid ovarian cancer or boost their survival should it develop, two new studies suggest. In fact, daily low-dose aspirin – the type many older women already take to help their hearts – was tied to a 10 percent reduction in developing ovarian cancer. It was also tied to as much as a 30 percent improvement in survival for ...

Infertility, Not Fertility Drugs, Linked to Raised Risk of Ovarian Cancer

Posted 16 days ago by Drugs.com

FRIDAY, July 6, 2018 – Fertility drugs do not increase a woman's risk of ovarian cancer, a new study suggests. It did find that infertility itself is associated with an increased risk of ovarian cancer. The researchers examined data from more than 58,000 women in Denmark who had infertility treatments (ART, or assisted reproduction technology) between 1994 and 2015. The investigators then ...

FDA Approves Genentech’s Avastin (bevacizumab) Plus Chemotherapy as a Treatment for Women With Advanced Ovarian Cancer Following Initial Surgery

Posted 14 Jun 2018 by Drugs.com

South San Francisco, CA – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following ...

Rubraca (rucaparib) Approved in the U.S. as Maintenance Treatment of Recurrent Ovarian Cancer

Posted 9 Apr 2018 by Drugs.com

BOULDER, Colo.--(BUSINESS WIRE)--Apr. 6, 2018-- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced that the U.S. Food and Drug Administration (FDA) has approved Rubraca (rucaparib) tablets for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA ...

Researchers Making Inroads Against Ovarian Cancer

Posted 29 Mar 2018 by Drugs.com

THURSDAY, March 29, 2018 – Ovarian cancer can be tough to beat, particularly if it returns after initial treatment, but new research offers a glimmer of hope. One study found that a new targeted "immunotherapy" to treat ovarian cancer that has come back looked promising in a small, early trial. Meanwhile, a second team of researchers discovered what appears to be a marker for patients who will ...

Could a Pap Test Spot More Than Just Cervical Cancer?

Posted 22 Mar 2018 by Drugs.com

WEDNESDAY, March 21, 2018 – Pap tests have helped drive down rates of cervical cancer, and a new study suggests they also could be used to detect other gynecologic cancers early. According to the study authors, tissue and fluid collected during a Pap test can detect endometrial and ovarian cancer in women when subjected to genetic testing. If this new test bears out, it would save thousands of ...

Dad Can Pass on Ovarian Cancer Genes, Too

Posted 16 Feb 2018 by Drugs.com

FRIDAY, Feb. 16, 2018 – A gene mutation that's passed down from a father is associated with earlier onset of ovarian cancer in daughters and prostate cancer in the father and his sons, a new study suggests. Previous research had shown that sisters of women with ovarian cancer have a higher risk for the disease than their mother, but the reasons for this were unclear. "Our study may explain why ...

Dad Can Pass on Ovarian Cancer Genes, Too

Posted 16 Feb 2018 by Drugs.com

FRIDAY, Feb. 16, 2018 – A gene mutation that's passed down from a father is associated with earlier onset of ovarian cancer in daughters and prostate cancer in the father and his sons, a new study suggests. Previous research had shown that sisters of women with ovarian cancer have a higher risk for the disease than their mother, but the reasons for this were unclear. "Our study may explain why ...

Ovarian Cancer Screening Still Ineffective, Not Recommended: Panel

Posted 13 Feb 2018 by Drugs.com

TUESDAY, Feb. 13, 2018 – Screening for ovarian cancer is not recommended for women with no signs or symptoms of the disease, newly released guidelines from the U.S. Preventive Services Task Force say. That represents no change in advice from the 2012 guidelines or the task force's draft recommendations issued in the summer of 2017. "Evidence shows that current screening methods do not prevent ...

'One-Stop' Blood Test for Cancer Shows Early Promise

Posted 18 Jan 2018 by Drugs.com

THURSDAY, Jan. 18, 2018 – In an early step toward "one-stop" screening for cancer, researchers report they've developed a blood test that can detect eight types of the disease. The blood test is dubbed CancerSEEK. It was able to catch cancer cases anywhere from 33 percent to 98 percent of the time, depending on the type. The accuracy range was better – 69 percent to 98 percent – when it came ...

The Pill Lowers Ovarian Cancer Risk, Even for Smokers

Posted 18 Jan 2018 by Drugs.com

THURSDAY, Jan. 18, 2018 – It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese. According to the study from the U.S. National Cancer Institute, these trends were also observed for endometrial cancer as well. Long-term use of the pill was linked to reductions in risk for both cancers, ...

New Trial Cancer Drug, Ulixertinib, Shows Promise Against Wide Range of Tumors

Posted 15 Dec 2017 by Drugs.com

FRIDAY, Dec. 15, 2017 – A new drug that targets a genetic flaw common to most cancer cells is showing potency against many tumor types. The preliminary trial of a drug called ulixertinib was conducted with 135 patients who had already failed treatments for one of a variety of advanced, solid tumors. Researchers led by Dr. Ryan Sullivan, of Massachusetts General Hospital, said ulixertinib did ...

Memo to Doctors: Spit Out the Bad News

Posted 27 Nov 2017 by Drugs.com

MONDAY, Nov. 27, 2017 – Doctors, don't be afraid to deliver bad news. Telling cancer patients the truth about their chances of survival does not harm a physician's relationship with those people. It could even make it better, according to a new study. "We hope this information will reassure clinicians about any negative impacts of these discussions on their relationships with patients," said ...

Know the Signs of Ovarian Cancer and Your Risks

Posted 10 Nov 2017 by Drugs.com

THURSDAY, Nov. 9, 2017 – About 22,440 American women will learn they have ovarian cancer this year, and more than 14,000 will die from the disease, according to the American Cancer Society. Often called a "silent killer," ovarian cancer is the 9th most common type of malignancy in women in the United States. Every woman should know the risks and symptoms of ovarian cancer. While the causes are ...

Health Tip: Being a Cancer Caregiver

Posted 27 Oct 2017 by Drugs.com

-- Helping to care for a person with cancer may involve issues ranging from understanding medication side effects and communicating with family to providing information to a patient's doctor to help determine if a treatment is working. The American Cancer Society offers this advice for cancer caregivers, recognizing they may feel overworked and under-appreciated: Always respect your feelings and ...

Page 1 2 3 ... Next

Ask a Question

Further Information

Related Condition Support Groups

Cancer

Related Drug Support Groups

methotrexate, Avastin, Taxol, carboplatin, cisplatin, Cytoxan, Zejula, cyclophosphamide, Gemzar, view more... gemcitabine, paclitaxel, doxorubicin, Adriamycin, etoposide, topotecan, Lynparza, bevacizumab, Alkeran, Platinol, Rubraca, Neosar, Hycamtin, Hexalen, olaparib, thiotepa, melphalan, Adriamycin PFS, Thioplex, Adriamycin RDF, Platinol-AQ, Cytoxan Lyophilized, Carboplatin Novaplus, Tepadina, altretamine, Doxil, Onxol, Toposar, Etopophos, VePesid, Paraplatin, niraparib, rucaparib, doxorubicin liposomal, dactinomycin, Cosmegen